Article

CMED Group joins AIXIAL

AIXIAL has announced the acquisition of UK headquartered CMED Group by ALTEN EUROPE. CMED is a technology led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and provision of data and analytic services. CMED also has a technology division that is the developer of encapsia, a clinical data suite purpose designed to support traditional, decentral, virtual and hybrid clinical trials.

AIXIAL Group continues to build a global presence in size and scale with over 1,000 employees across the United States and Europe.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.